Search research articles
Contact Us
Filters
Showing results (1-10 of 33) with videos related to
Page
of 4
Sort By:
Hospital Practice (Office Ed.)
|
October 30, 1992
Intravenous IgG for treatment of autoimmune disease
D P Schenkein
Cancer Treatment and Research
|
January 19, 1999
Therapy of diffuse aggressive lymphomas
Y Koc, D P Schenkein
JAMA
|
July 14, 1993
Hematology
K B Miller, D P Schenkein
The Journal of Biological Chemistry
|
January 10, 1980
Phenylpropynal, a specific, irreversible, non-beta-lactam inhibitor of beta-lactamases
D P Schenkein, R F Pratt
The New England Journal of Medicine
|
March 27, 1997
Neoplasms and transplantation - trading swords for plowshares
D P Schenkein, R S Schwartz
Seminars in Hematology
|
July 1, 1992
An assessment of the safety and tolerability of immune globulin intravenous (human) Sandoglobulin prepared in sterile water or 5% dextrose at various concentrations
K B Miller, D P Schenkein, T Fogaren
Clinical Pharmacy
|
July 1, 1992
Safety and tolerability of an intravenous immune globulin at various concentrations in 5% dextrose injection or sterile water for injection
K B Miller, D P Schenkein, R L Wasserman
The Journal of Biological Chemistry
|
December 15, 1987
Kinetics and mechanism of inactivation of the RTEM-2 beta-lactamase by phenylpropynal. Identification of the characteristic chromophore
M E Grace, D P Schenkein, R F Pratt
Annals of Internal Medicine
|
September 1, 1986
Accelerated bone formation causing profound hypocalcemia in acute leukemia
D P Schenkein, W C O'Neill, J Shapiro, et al.
Cancer
|
March 26, 1999
Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation
Y Koc, K B Miller, D P Schenkein, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 33) with videos related to
Sort By:
Page
of 4
Hospital Practice (Office Ed.)
|
October 30, 1992
Intravenous IgG for treatment of autoimmune disease
D P Schenkein
Cancer Treatment and Research
|
January 19, 1999
Therapy of diffuse aggressive lymphomas
Y Koc, D P Schenkein
JAMA
|
July 14, 1993
Hematology
K B Miller, D P Schenkein
The Journal of Biological Chemistry
|
January 10, 1980
Phenylpropynal, a specific, irreversible, non-beta-lactam inhibitor of beta-lactamases
D P Schenkein, R F Pratt
The New England Journal of Medicine
|
March 27, 1997
Neoplasms and transplantation - trading swords for plowshares
D P Schenkein, R S Schwartz
Seminars in Hematology
|
July 1, 1992
An assessment of the safety and tolerability of immune globulin intravenous (human) Sandoglobulin prepared in sterile water or 5% dextrose at various concentrations
K B Miller, D P Schenkein, T Fogaren
Clinical Pharmacy
|
July 1, 1992
Safety and tolerability of an intravenous immune globulin at various concentrations in 5% dextrose injection or sterile water for injection
K B Miller, D P Schenkein, R L Wasserman
The Journal of Biological Chemistry
|
December 15, 1987
Kinetics and mechanism of inactivation of the RTEM-2 beta-lactamase by phenylpropynal. Identification of the characteristic chromophore
M E Grace, D P Schenkein, R F Pratt
Annals of Internal Medicine
|
September 1, 1986
Accelerated bone formation causing profound hypocalcemia in acute leukemia
D P Schenkein, W C O'Neill, J Shapiro, et al.
Cancer
|
March 26, 1999
Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation
Y Koc, K B Miller, D P Schenkein, et al.
Page
of 4